Table 2.
Pharmacokinetic parameters at steady state for a model escitalopram normal metabolizer with concurrent cannabinoid use assuming a 25% reduction in clearance based on Bansal et al. [31].
| THC or Low-Dose CBD 1 | ||
|---|---|---|
| − | + | |
| t1/2 (h) | 21.3 | 28.3 |
| AUC24, 10 mg q.d. (days ng/mL) | 17.1 | 23.1 |
| Cmax, 10 mg q.d. (ng/mL) | 22.7 | 28.4 |
| AUC24, 20 mg q.d. (days ng/mL) | 34.1 | 46.1 |
| Cmax, 20 mg q.d. (ng/mL) | 45.4 | 56.9 |
1 Abbreviations: t1/2, half-life; AUC24, area under the curve (24-h); q.d., quaque die (once daily); THC, tetrahydrocannabinol; CBD, cannabidiol.